Page 36 - 2018_10-Haematologica-web

P. Valent et al.
poiesis and regulation of iron status in iron loading anaemias. Br J Haematol. 2016;172 (4):512-523.
14. Shimamura A. Aplastic anemia and clonal evolution: germ line and somatic genetics. Hematology Am Soc Hematol Educ Program. 2016;2016(1):74-82.
15. Hasserjian RP, Howard J, Wood A, Henry K, Bain B. Acute erythremic myelosis (true ery- throleukaemia): a variant of AML FAB-M6. J Clin Pathol. 2001;54(3):205-209.
16. Prchal JT. Polycythemia vera and other pri- mary polycythemias. Curr Opin Hematol. 2005;12(2):112-116.
17. Wang SA, Hasserjian RP. Erythroid prolifera- tions in myeloid neoplasms. Hum Pathol. 2012;43(2):153-164.
18. Wang W, Wang SA, Medeiros LJ, Khoury JD. Pure erythroid leukemia. Am J Hematol. 2017;92(3):292-296.
19. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require ery- thropoietin or the erythropoietin receptor. Cell. 1995;83(1):59-67.
20. Cantor AB, Orkin SH. Transcriptional regu- lation of erythropoiesis: an affair involving multiple partners. Oncogene. 2002;21(21): 3368-3376.
21. Donovan A, Andrews NC. The molecular regulation of iron metabolism. Hematol J. 2004;5(5):373-380.
22. Kim SI, Bresnick EH. Transcriptional control of erythropoiesis: emerging mechanisms and principles. Oncogene. 2007;26(47):6777- 6794.
23. Semenza GL. Regulation of oxygen home- ostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009;24:97-106.
24. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013; 27(1):41-53.
25. Hermine O, Arlet JB, Ribeil JA, Guillerm F, Vandekerkhove J, Courtois G. HSP70, an erythropoiesis regulator that determines the fate of erythroblasts between death and dif- ferentiation. Transfus Clin Biol. 2013;20(2): 144-147.
26. Kautz L, Nemeth E. Molecular liaisons between erythropoiesis and iron metabo- lism. Blood. 2014;124(4):479-482.
27. Simon MC, Pevny L, Wiles MV, Keller G, Costantini F, Orkin SH. Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells. Nat Genet. 1992;1(2):92-98.
28. Simon MC. Transcription factor GATA-1 and erythroid development. Proc Soc Exp Biol Med. 1993;202(2):115-121.
29. Kaneko H, Shimizu R, Yamamoto M. GATA factor switching during erythroid differenti- ation. Curr Opin Hematol. 2010;17(3):163- 168.
30. Ribeil JA, Zermati Y, Vandekerckhove J, et al. Hsp70 regulates erythropoiesis by pre- venting caspase-3-mediated cleavage of GATA-1. Nature. 2007;445(7123):102-105.
31. Arlet JB, Ribeil JA, Guillem F, et al. HSP70 sequestration by free b-globin promotes ineffective erythropoiesis in b-thalassaemia. Nature. 2014;514(7521):242-246
32. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol. 2008;141(3):325-334.
33. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A red carpet for iron metabolism. Cell. 2017;168(3):344-361.
34. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythro- ferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.
35. Coulon S, Dussiot M, Grapton D, et al. Polymeric IgA1 controls erythroblast prolif- eration and accelerates erythropoiesis recov- ery in anemia. Nat Med. 2011;17(11):1456- 1465.
36. Frisan E, Vandekerckhove J, de Thonel A, et al. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syn- dromes. Blood. 2012;119(6):1532-1542.
37. Gastou M, Rio S, Dussiot M, et al. The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. Blood Adv. 2017;1(22):1959-1976.
38. Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res. 2003;282 (2):110-120.
39. Socolovsky M, Murrell M, Liu Y, Pop R, Porpiglia E, Levchenko A. Negative autoreg- ulation by FAS mediates robust fetal ery- thropoiesis. PLoS Biol. 2007;5(10):e252.
40. Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, Socolovsky M. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythro- poietic stress response in vivo. Blood. 2006;108(1):123-133.
41. Wang Q, Huang Z, Xue H, et al. MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood. 2008;111(2):588-595.
42. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects inef- fective erythropoiesis in b-thalassemia. Nat Med. 2014;20(4):398-407.
43. Koulnis M, Porpiglia E, Hidalgo D, Socolovsky M. Erythropoiesis: from molec- ular pathways to system properties. Adv Exp Med Biol. 2014;844:37-58.
44. Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis. 2010;56(3):558-565.
45. Kim YC, Mungunsukh O, Day RM. Erythropoietin regulation by angiotensin II. Vitam Horm. 2017;105:57-77.
46. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol. 2009;4:489-515.
47. Silva B, Faustino P. An overview of molecu- lar basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta. 2015;1852(7):1347-1359.
48. Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation. Curr Opin Hematol. 2016;23(3):189-197.
49. Uras IZ, Scheicher RM, Kollmann K, et al. Cdk6 contributes to cytoskeletal stability in erythroid cells. Haematologica. 2017;102 (6):995-1005.
50. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syn- dromes: consensus statements and report from a working conference. Leuk Res. 2007;31(6):727-736.
51. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
52. Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget 2017:8(43):73483-73500.
53. Malcovati L, Della Porta MG, Lunghi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia.
2005; 19(5):776-783.
54. Della Porta MG, Malcovati L, Invernizzi R,
et al. Flow cytometry evaluation of ery- throid dysplasia in patients with myelodys- plastic syndrome. Leukemia. 2006;20(4):549-555.
55. Xu F, Wu L, He Q, Zhang Z, Chang C, Li X. Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes. Intern Med J. 2012;42(4):401-411.
56. Eidenschink Brodersen L, Menssen AJ, et al. Assessment of erythroid dysplasia by "dif- ference from normal" in routine clinical flow cytometry workup. Cytometry B Clin Cytom. 2015;88(2):125-135.
57. Bühring HJ, Müller T, Herbst R, et al. The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages. Leukemia. 1996;10(1):106-116.
58. Bauer K, Machherndl-Spandl S, Suessner S, et al. Identification of CAR as a novel medi- ator of erythroid differentiation and migra- tion that is specifically downregulated in erythropoietic progenitor cells in patients with MDS. Blood. 2014;124(21):1570.
59. Chasis JA, Mohandas N. Erythroblastic islands: niches for erythropoiesis. Blood. 2008;112(3):470-478.
60. Buesche G, Teoman H, Giagounidis A, et al. Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes. Haematologica. 2016;101(5):e177-e181.
61. Moriyama Y, Sato M, Kinoshita Y. Studies on hematopoietic stem cells: XI. Lack of ery- throid burst-forming units (BFU-E) in patients with aplastic anemia. Am J Hematol. 1979;6(1):11-16.
62. Amato D, Khan NR. Erythroid burst forma- tion in cultures of bone marrow and periph- eral blood from patients with refractory ane- mia. Acta Haematol. 1983;70(1):1-10.
63. Geissler K, Hinterberger W, Jäger U, et al. Deficiency of pluripotent hemopoietic pro- genitor cells in myelodysplastic syndromes. Blut. 1988;57(1):45-49.
64. Manor D, Rachmilewitz EA, Fibach E. Improved method for diagnosis of poly- cythemia vera based on flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture. Am J Hematol. 1997;54(1):47-52.
65. Geissler K, Ohler L, Födinger M, et al. Interleukin-10 inhibits erythropoietin-inde- pendent growth of erythroid bursts in patients with polycythemia vera. Blood. 1998;92(6):1967-1972.
66. Sifakis S, Pharmakides G. Anemia in preg- nancy. Ann N Y Acad Sci. 2000;900:125-136. 67. Milman N. Postpartum anemia I: definition, prevalence, causes, and consequences. Ann
Hematol. 2011;90(11):1247-1253.
68. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PH, Newman AB, Cushman M. A prospective study of anemia status, hemo- globin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med. 2005;165(19):2214-
2220.
69. Chaves PH, Xue QL, Guralnik JM, Ferrucci
L, Volpato S, Fried LP. What constitutes nor- mal hemoglobin concentration in communi- ty-dwelling disabled older women? J Am Geriatr Soc. 2004;52(11):1811-1816.
70. Steensma DP, Tefferi A. Anemia in the elder- ly: how should we define it, when does it matter, and what can be done? Mayo Clin
1602
haematologica | 2018; 103(10)